Growth Hormone · Endocrine
CJC-1295 (DAC)
Also known as: CJC-1295 with DAC, DAC:GRF, CJC-1295 with Drug Affinity Complex
A long-acting GHRH analog conjugated to a Drug Affinity Complex for albumin binding, originally developed by ConjuChem and never advanced to Phase 3.
Sign in to add to watchlistEvidence strength
Strength of human clinical evidence — A (strongest) to D (mostly preclinical). This reflects research maturity, not safety or suitability.
Vial Theory provides educational research summaries only. Content is not medical advice, diagnosis, treatment, dosing guidance, or individualized suitability screening. Regulatory status can change over time and varies by jurisdiction.
Key Takeaways
- ›CJC-1295 (DAC) is a long-acting GHRH analog that binds albumin to stay active for days, causing continuous growth-hormone stimulation.
- ›Human evidence is limited to one small early-phase study; development was halted with no Phase 3 data.
- ›It is not approved and remains on the FDA's Category 2 bulk-substances list.
- ›Long-term safety of continuous growth-hormone-axis stimulation is unknown.
- ›Online claims exceed the evidence. Speak with a licensed healthcare professional before any health decisions.
What It Is
CJC-1295 with DAC is a stabilized 30-residue analog of GHRH (1-29) that incorporates a maleimidopropionyl Drug Affinity Complex (DAC) moiety that forms a covalent bond with plasma albumin after administration. The albumin conjugation substantially extends the compound's circulating half-life — measured in days — and produces sustained GHRH-receptor stimulation rather than the pulsatile pattern produced by short-acting analogs.
The compound was developed by the Canadian company ConjuChem during the 2000s using their broader DAC platform, which was applied to multiple peptide drug candidates. The DAC version of CJC-1295 was the lead growth-hormone-axis program, with published Phase 1/2 data from Teichman and colleagues in 2006 establishing its pharmacokinetics and effects on GH and IGF-1.
Unlock the full CJC-1295 (DAC) research report
Vial+ opens the mechanism breakdown, evidence graphs, potential benefits, safety considerations, regulatory status, a plain-language explainer, and 3 cited sources.
Get Vial+ — $20 one-timeLifetime access · the community forum stays free.
Disclaimer: This content is for educational and research purposes only and is not medical advice. Always consult a licensed healthcare professional before making health-related decisions.